 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insmed (NASDAQ:INSM  Get Free Report) had its price target hoisted by Evercore ISI from $32.00 to $42.00 in a research note issued on Thursday, MarketBeat reports. The firm presently has an...

Insmed (NASDAQ:INSM) PT Raised to $42.00 at Evercore ISI

Over the last three days, A.I.dvisor has detected that INSM's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Insmed (INSM, $26.26) Aroon Indicator entered an Uptrend on September 08, 2023.

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire BRIDGEWATER, N.J., Sept. 8, 2023 BRIDGEWATER...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference PR Newswire BRIDGEWATER, N.J., Sept...

Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Insmed (NASDAQ:INSM  Get Free Report) had its price objective increased by research analysts at Bank of America from $35.00 to $37.00 in a research note issued on Wednesday, FlyOnTheWall...

Insmed (NASDAQ:INSM) Given New $37.00 Price Target at Bank of America

This indicator may be signaling INSM's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Insmed (INSM, $22.64) entered Uptrend as Momentum indicator ascends above 0 level on Sep 01, 2023

In a report released yesterday, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Insmed (INSM Research Report), with a price t... In a report released yesterday, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Insmed (INSM &#8211...

Mizuho Securities Sticks to Their Buy Rating for Insmed (INSM)

Insmed Incorporated (NASDAQ:INSM Get Free Report) has earned a consensus rating of Buy from the twelve research firms that are covering the company, MarketBeat Ratings reports. Twelve research analysts have rated the stock with a buy recommendation. The average twelve-month target price among ...

Insmed Incorporated (NASDAQ:INSM) Receives $43.85 Consensus PT from Brokerages

Insmed (INSM, $22.09) entered Uptrend as Momentum indicator ascends above 0 level on Aug 23, 2023

Connor Clark & Lunn Investment Management Ltd. lessened its position in Insmed Incorporated (NASDAQ:INSM  Free Report) by 1.9% in the first quarter, according to the company in its most...

Connor Clark & Lunn Investment Management Ltd. Lowers Position in Insmed Incorporated (NASDAQ:INSM)

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Watchers	1,702
52-Wk Low	$16.04
52-Wk High	$27.59

Market Cap	$3.76B
Volume (M)	841,706.00
52-Wk High	$27.59
52-Wk Low	$16.04

INSM Insmed Inc

About

Feed

News

Sentiment

Earnings

Fundamentals